ENCell Co., Ltd.
Founded in 2018 and listed on the KOSDAQ in 2024, ENCell is a cell and gene therapy CDMO and next-generation mesenchymal stem cell drug developer.
Price
Change
Market cap
Products & technology
- EN001-CMTCharcot-Marie-Tooth disease therapy (next-gen mesenchymal stem cell therapy)
- EN001-DMDDuchenne muscular dystrophy therapy (next-gen mesenchymal stem cell therapy)
- EN001-SPSarcopenia therapy (next-gen mesenchymal stem cell therapy)
- Advanced biopharmaceutical CDMO serviceContract development and manufacturing for cell therapy, organoid-based therapy, and gene therapy
Regulatory approvals
1 Orphan Drug designations · 2022
- Orphan1. 주성분: 동종탯줄유래중간엽줄기세포 (5.0x10^6), 2. 현탁화제: 동결보존배지 (10mL)2022-05-27Orphan Drug designation · in development20220087792
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2021–2024 (Phase 1/2 2 · Phase 1 2 · Phase 1/2a 1)
- Phase 1/2aEN0012024-06-27
1 trial site
- Phase 1/2EN0012023-09-19
1 trial site
- Phase 1/2EN0012023-06-22
5 trial sites
- Phase 1EN0012021-06-29
1 trial site
- Phase 1EN0012021-05-04
1 trial site
R&D and key agreements
Source: DART corporate disclosureEN001-CMT · 샤르코-마리-투스병(CMT) · 임상2상 진행 예정(조건부허가 신청 계획) · Designated an orphan drug in development in April 2022.
EN001-DMD · 듀센 근디스트로피(DMD) · 임상2상 진행 예정(조건부허가 신청 계획) · Designated an orphan drug in development in May 2022.
조직특이 타게팅 AAV 플랫폼 · 비임상 검증 후 라이선싱 추진 · Developing a tissue-specific targeted AAV platform, including a muscle-targeting AAV platform, to be validated preclinically and then licensed out.
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition